medigraphic.com

2018, Number 1

<< Back Next >>

Cir Cir 2018; 86 (1)

Secondary sclerosing cholangitis in critically ill patients

Peña-Pérez CA, Díaz Ponce-Medrano JA

Language: Spanish
References: 54
Page: 56-62
PDF size: 278.38 Kb.


ABSTRACT

Primary sclerosing cholangitis (PSC) is a rare idiopathic condition with immunopathogenic mechanisms where there is chronic progressive destruction of the biliary tree. Secondary sclerosing cholangitis (SSC) is clinically comparable to PSC, but is caused by specific processes which directly damage the biliary tree; examples include recurrent pancreatitis, bile duct malignancy, congenital bile duct abnormalities. A new cause of SSC has been described during or following significant critical illness associated with severe respiratory insufficiency, vasopressor requirement, shock and sepsis. This condition rapidly progresses to cirrhosis, frequently requiring liver transplantation for definitive management.


REFERENCES

  1. Schmitt M, Kölbel CB, Müller MK, Verbeke CS, Singer MV. Sclerosing cholangitis after burn injury. Z Gastroenterol. 1997;35:929-34.

  2. Gelbmann CM, Rümmele P, Wimmer M, Hofstädter F, Gohlmann B, Endlicher E, et al. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol. 2007;102:1221-9.

  3. Engler S, Elsing C, Flechtenmacher C, Theilmann L, Stremmel W, Stiehl A. Progressive sclerosing cholangitis after septic shock: a new variant of vanishing bile duct disorders. Gut. 2003;52:688-93.

  4. Jaeger C, Mayer G, Henrich R, Gossner L, Rabenstein T, May A, et al. Secondary sclerosing cholangitis after long-term treatment in an intensive care unit: a clinical presentation, endoscopic findings, treatment, and follow-up. Endoscopy. 2006;38:730-4.

  5. Hill AB. The environment and disease. Association or causation? Proc R Soc Med. 1965;58:265-300.

  6. Sherlock S. Chronic cholangitides: aetiology, diagnosis, and treatment. BMJ. 1968;3:515-21.

  7. Hohn D, Melnick J, Stagg R, Altman D, Friedman M, Ignoffo R, et al. Biliary sclerosis in patients receiving hepatic arterial infusion of floxuridine. J Clin Oncol. 1985;3:98-102.

  8. Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology. 1989;9:215-8.

  9. Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology. 2010;52:1489-96.

  10. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 1993;75:451-62.

  11. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammation cholangitis and hepato-carcinogenesis. Am J Pathol. 1994;145:1237-45.

  12. Popov Y, Patsenker E, Pickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol. 2005; 43:1045-54.

  13. Strazzabosco M, Spirli C, Okolicsanyi L. Pathophysiology of the intrahepatic biliary epithelium. J Gastroenterol Hepatol. 2000;15:244-53.

  14. Lautt WW. Regulatory processes interacting to maintain hepatic blood flow constancy: vascular compliance, hepatic arterial buffer response, hepatorenal reflex, liver regeneration, escape from vasoconstriction. Hepatol Res. 2007;37:891-903.

  15. Bahloul M, Samet M, Chaari A, Ben Aljia N, Ben Mbarek MN, Chelly H, et al. Use of catecholamines for shock a continuous debate! Tunis Med. 2012;90:291-9.

  16. Hiltebrand LB, Krejci V, Sigurdsson GH. Effects of dopamine, dobutamine, and dopexamine on microcirculatory blood flow in the gastrointestinal tract during sepsis and anesthesia. Anesthesiology. 2004;100:1188-97.

  17. Meier-Hellmann A, Reinhart K, Bredle DL, Specht M, Spies CD, Hannermann L. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med. 1997;25:399-404.

  18. Martikainen TJ, Tenhunen JJ, Giovannini I, Uusaro A, Roukonen E. Epinephrine induces tissue perfusion deficit in porcine endotoxin shock: evaluation by regional CO(2) content gradients and lactate-to-pyruvate ratios. Am J Physiol Gastrointest Liver Physiol. 2005;288:G586-92.

  19. Deltere P, Valla DC. Ischemic cholangiopathy. J Hepatol. 2006;44:806-17.

  20. Sonomura T. Optimal size of embolic material in transcatheter arterial embolization of the liver. Nihon Igaku Hoshasen Gakkai Zasshi. 1994; 54:489-99.

  21. Doppman JL, Dunnick NR, Girton M, Fauci AS, Popovsky MA. Bile duct cysts secondary to liver infarcts: report of a case and experimental production by small vessel hepatic artery occlusion. Radiology. 1979;130:1-5.

  22. Differding JA, Underwood SJ, Van PY, Khaki RA, Spoerke NJ, Schreiber MA. Trauma induces a hypercoagulable state that is resistant to hypothermia as measured by thrombelastogram. Am J Surg. 2011;201 587-91.

  23. Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma. 2008;64:1211-7.

  24. Floccard B, Rugeri L, Faure A, Saint Denis M, Boyle EM, Peguet O, et al. Early coagulopathy in trauma patients: an on-scene and hospital admission study. Injury. 2012;43:26-32.

  25. Hunt BJ, Parrat RN, Segal HC, Sheikh S, Kallis P, Yacoub M. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg. 1998;65:712-8.

  26. Stahl RL, Duncan A, Hooks MA, Henderson JM, Millikan WJ, Warren WD. A hypercoagulable state follows orthotopic liver transplantation. Hepatology. 1990;12:553-8.

  27. Lison S, Weiss G, Spannagl M, Heindl B. Postoperative changes in procoagulant factors after major surgery. Blood Coagul Fibrinolysis. 2011;22:190-6.

  28. Kirby DF, Blei AT, Rosen ST, Vogelzang RL, Neiman HL. Primary sclerosing cholangitis in the presence of a lupus anticoagulant. Am J Med. 1986;81:1077-80.

  29. Viola S, Meyer M, Fabre M, Tounian P, Goddon R, Dechelotte P, et al. Ischemic necrosis of bile ducts complicating Schönlein-Henoch purpura. Gastroenterology. 1999;117:11-4.

  30. Le Thi HD, Valla D, Franco D, Wechsler B, De Gramont A, Auperin A, et al. Cholangitis associated with paroxysmal nocturnal hemoglobinuria: another instance of ischemic cholangiopathy? Gastroenterology. 1995; 109:1338-43.

  31. Lamy P, Valla D, Bourgeois P, Rueff B, Benhamou JP. Primary sclerosing cholangitis and systemic lupus erythematosus. Gastroenterol Clin Biol. 1988;12:962-4.

  32. Audan A, Bruley Des Varannes S, Georgelin T, Sagan C, Cloarec D, Serraz H, et al. Primary sclerosing cholangitis and systemic lupus erythematosus. Gastroenterol Clin Biol. 1995;19:123-6.

  33. Chernysheva GA, Plotnikov MB, Smol’yakova VI, Avdoshin AD, Saratikov AS, Sutormina TG. Relationship between rheological and hemodynamic changes in rats with crush syndrome. Bull Exp Biol Med. 2000;130:1048-50.

  34. Heidenhain C, Pratschke J, Puhl G, Neumann U, Pascher A, Veltzke-Schlieker W, et al. Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation. Transpl Int. 2010;23:14-22.

  35. Moench C, Moench K, Lohse AW, Thies J, Otto G. Prevention of ischemic- type biliary lesions by arterial back-table pressure perfusion. Liver Transpl. 2003;9:285-9.

  36. de Morais BS, Sanches MD, Ribeiro DD, Lima AS, de Abreu Ferrari TC, Duarte MM, et al. Association between the use of blood components and the five-year mortality after liver transplant. Rev Bras Anestesiol. 2011;61:286-92.

  37. Ramos E, Dalmau A, Sabaté A, Lama C, Lladó l, Figueras J, et al. Intraoperative red blood cell transfusion in liver transplantation: influence on patient outcome, prediction of requirements, and measures to reduce them. Liver Transpl. 2003;9:1320-7.

  38. Van Bommel J, de Korte D, Lind A, Seigemund M, Trouwborst A, Verhoeven AJ, et al. The effect of the transfusion of stored RBCs on intestinal microvascular oxygenation in the rat. Transfusion. 2001; 41:515-23.

  39. Fujita Y. Effects of PEEP on splanchnic hemodynamics and blood volume. Acta Anaesthesiol Scand. 1993;37:427-31.

  40. Kubitz R, Wettstein M, Warskulat U, Häussinger D. Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology. 1999;16:401-10.

  41. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology. 1997;113:255-64.

  42. Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, et al. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology. 1998;28:1637-44.

  43. Hartmann G, Kim H, Piquette-Miller M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int Immunopharmacol. 2001;1:189-99.

  44. Spirlì C, Nathanson MH, Fiorotto R, Duner E, Denson LA, Sanz JM, et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology. 2001;121:156-69.

  45. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:117-23.

  46. Deltenre P, Valla DC. Ischemic cholangiopathy. J Hepatol. 2006; 44:806-17.

  47. Sakrak O, Akpinar M, Bedirli A, Akyurek N, Aritas Y. Short and long-term effects of bacterial translocation due to obstructive jaundice on liver damage. Hepatogastroenterology. 2003;50:1542-6.

  48. Sherlock S. Pathogenesis of sclerosing cholangitis: the role of nonimmune factors. Semin Liver Dis. 1991;11:5-10.

  49. Leonhardt S, Veltz-Schlieker W, Adler A, Schott E, Eurich D, Faber W, et al. Secondary sclerosing cholangitis in critically ill patients: clinical presentation, cholangiography features, natural history, and outcome. Medecine. 2015;94:e2188.

  50. Weber C, Kuhlencordt R, Grotelueschen R, Wedegaertner U, Ang TL, Adam G, et al. Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis. Endoscopy. 2008;40:739-45.

  51. Voigtländer T, Leuchs E, Vonberg RP, Solbach P, Manns MP, Suerbaum S, et al. Microbiological analysis of bile and its impact in critically ill patients with secondary sclerosing cholangitis. J Infect. 2015;70:483-90.

  52. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology. 2004;127:1565-77.

  53. Weisner RH, Porayko MK, Dickson ER, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology. 1992;16:1290-9.

  54. Farger O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery. 1995;117:146-55.




2020     |     www.medigraphic.com